E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers N > Headlines for NicOx SA > News item
Published on 11/2/2006 in the Prospect News Biotech Daily.

Jefferies starts coverage of NicOx at buy

Jefferies & Co., Inc. analyst Robin Campbell began coverage of NicOx with a buy rating on the belief that HCT3012 could be uniquely positioned to fill a therapeutic vacuum left by the COX-2s. Phase 3 development is needed for convincing efficacy, according to the analyst. Shares of the Sophia-Antipolis, France-based pharmaceutical company were unchanged at €17.00. (Pink Sheets: NICXF)


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.